Thought Leadership at Locust Walk Partners

We issued a press release last week about speaking engagements that Jay and I will be participating in. Most notably is the FierceBiotech webinar, which is receiving lot of of press in their email blasts. We plan to present the results of the survey that we are...

Negotiate the Exit before the Entry

Jay and I recently had a nice chat with a prominent entrepreneur. He has worked on many successful startups that raised a lot of venture capital money and eventually went public and/or sold. His current start-up is having a bit more difficulty than his previous...

BioPharma Licensing in 2009: Staying Above the Noise

We’ve recently posted on this Blog that licensing transactions appear to be overtaking biotech mergers and acquisitions as the means for investors and management teams to exit and realize value from their companies. Proceeds from backup assets and earlier pipeline...

The Venture Investing Strategy for Tough Times

I had an interesting conversation yesterday with a good buddy of mine who works at a top venture capital firm. I mentioned that Locust Walk Partners is considering doing company formation work. I wanted to know if he thought that we were crazy. He responded that he...

Is Licensing the new M&A?

For the past decade, the number of venture backed companies purchased by big pharma has not changed materially. There are only so many big companies and only so many deals that each company can do. With the renewal of consolidation between large companies...